Safety and efficacy of intratumoural anti-CTLA4 with intravenous anti-PD1

The phase 1b NIVIPIT trial demonstrated that combining intratumoural ipilimumab (anti-CTLA4) with intravenous nivolumab (anti-PD1) improves safety and efficacy compared to intravenous delivery alone. The study, published in Nature, highlights a novel approach to cancer immunotherapy.